Myllia Biotechnology

At Myllia, we perform high-content CRISPR screens in advanced cellular models such as primary human immune cells to map the impact of thousands of genetic perturbations at single-cell resolution – a new paradigm to nominate the best possible targets for your drug discovery campaign. Pooled CRISPR screens accelerate drug discovery across many therapeutic areas and help unravel gene regulatory networks. We utilize CRISPR knockout, CRISPR interference and CRISPR activation for genetic perturbation combined with high-content functional genomics read-outs. 

Myllia’s CROP-seq perturbation datasets can also be utilized at unprecedented scale to enable the training of artificial intelligence (AI) models. For instance, such AI/ML-based foundation models help create digital avatars of human cells to predict phenotypic changes caused by CRISPR perturbation and “matched” drug perturbation data.